Cardiol Therapeutics Publishes Recurrent Pericarditis Phase II Data
TORONTO, Ontario, July 14, 2026 Cardiol Therapeutics Inc. has announced the publication of its Phase II MAvERIC clinical trial...
CardiolRx
Advertisement
CardiolRx Phase II Results Support Heart Disease Therapy
TORONTO, ON, May 7, 2026 Cardiol Therapeutics Inc. announced that results from its Phase II MAvERIC study evaluating CardiolRx™...
Cardiol Reaches 50% Enrollment in Phase III MAVERIC Trial
Toronto, Jan. 13, 2026 — Cardiol Therapeutics Inc. announced that it has surpassed the 50% patient enrollment milestone in...
CardiolRx Phase II Trial Shows Structural Heart Recovery in Myocarditis
Toronto, December 1, 2025 — New clinical data from the Phase II ARCHER trial reveal that CardiolRx™, Cardiol Therapeutics’...
Cardiol Therapeutics Gains Major Patent Boost for Heart Drugs
NEW YORK, November 13, 2024 — Cardiol Therapeutics has secured a U.S. patent allowance protecting its next-generation cardiac therapies...
Advertisement
